Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 30

Sort by

Sort Order Select

Journal Articles

BDR in newly diagnosed patients with WM: final analysis of a phase 2 study after a minimum follow-up of 6 years

Maria Gavriatopoulou, Ramón García-Sanz, Efstathios Kastritis, Pierre Morel, Marie-Christine Kyrtsonis, Eurydiki Michalis, Zafiris Kartasis, Xavier Leleu, Giovanni Palladini, Alessandra Tedeschi, Dimitra Gika, Giampaolo Merlini, Pieter Sonneveld, Meletios A. Dimopoulos

Blood (2017) 129 (4): 456–459.

https://doi.org/10.1182/blood-2016-09-742411

Published: 2017

Journal Articles

Real-World Data on Clinical Characteristics, Prognosis and Outcome of Primary Plasma Cell Leukemia: A Study of the Greek Myeloma Study Group in the Era of Novel Agents

Blood (2016) 128 (22): 4490.

https://doi.org/10.1182/blood.V128.22.4490.4490

Published: 2016

Journal Articles

Hypercalcemia Remains an Adverse Prognostic Factor for Newly Diagnosed Patients with Symptomatic Multiple Myeloma in the Era of Novel Anti-Myeloma Therapies, Independently of Age, ISS Stage and Treatment Type: An Analysis of 2129 Patients

Blood (2014) 124 (21): 2113.

https://doi.org/10.1182/blood.V124.21.2113.2113

Published: 2014

Journal Articles

No Survival Improvement for Central Nervous System Multiple Myeloma By the Use of Novel Anti-Myeloma Agents: The Greek Myeloma Study Group Experience

Blood (2014) 124 (21): 4752.

https://doi.org/10.1182/blood.V124.21.4752.4752

Published: 2014

Journal Articles

Preserved Levels Of Uninvolved Immunoglobulins Are Associated With Better Overall Survival In Patients With Multiple Myeloma Independently Of Disease Burden: A Role For The Immune System?

Blood (2013) 122 (21): 1866.

https://doi.org/10.1182/blood.V122.21.1866.1866

Published: 2013

Journal Articles

Competing Risk Survival Analysis In Patients With Symptomatic Waldenström’s Macroglobulinemia (WM): Disease Unrelated Mortality Accounts For Differences In Survival In Patients >75 Years

Efstathios Kastritis, Marie-Christine Kyrtsonis, MD, Evdoxia Hatjiharissi, Argiris S. Symeonidis, Amalia Vassou, Panagiotis Repousis, Sosana Delimpasi, Anastasia Sioni, Eurydiki Michalis, Michalis Michael, Elina Vervessou, Ekaterini Stefanoudaki, Michael Voulgarelis, Costas Tsatalas, Evangelos Terpos, Meletios A. Dimopoulos, MD

Blood (2013) 122 (21): 3197.

https://doi.org/10.1182/blood.V122.21.3197.3197

Published: 2013

Journal Articles

Primary therapy of Waldenström macroglobulinemia (WM) with weekly bortezomib, low-dose dexamethasone, and rituximab (BDR): long-term results of a phase 2 study of the European Myeloma Network (EMN)

Meletios A. Dimopoulos, Ramón García-Sanz, Maria Gavriatopoulou, Pierre Morel, Marie-Christine Kyrtsonis, Eurydiki Michalis, Zafiris Kartasis, Xavier Leleu, Giovanni Palladini, Alessandra Tedeschi, Dimitra Gika, Giampaolo Merlini, Efstathios Kastritis, Pieter Sonneveld

Blood (2013) 122 (19): 3276–3282.

https://doi.org/10.1182/blood-2013-05-503862

Published: 2013

Includes: Supplemental data

Journal Articles

The Chronic Kidney Disease-Epidemiology Collaboration-Cystatin C (CKD-EPI-CysC) Equation Has an Independent Prognostic Value for Overall Survival in Newly-Diagnosed Patients with Symptomatic Multiple Myeloma: Comparison with 3 Other Equations for GFR Estimation

Meletios A Dimopoulos, MD, Efstathios Kastritis, Eirini Katodritou, Anastasia Pouli, Eurydiki Michalis, Dimitrios Christoulas, Maria Gkotzamanidou, Ioannis Papassotiriou, Konstantinos Zervas, Evangelos Terpos

Blood (2012) 120 (21): 1849.

https://doi.org/10.1182/blood.V120.21.1849.1849

Published: 2012

Journal Articles

Primary Treatment of Waldenstrom's Macroglobulinemia with Dexamethasone, Rituximab and Cyclophosphamide (DRC): Final Analysis of a Phase II Study

Meletios A. Dimopoulos, MD, Maria Roussou, Efstathios Kastritis, Evdoxia Hadjiharissi, Marie-Christine Kyrtsonis, Argiris Symeonidis, MD, PhD, Panagiotis Repoussis, Eurydiki Michalis, Sosana Delimpasi, Konstantinos Tsatalas, Panagiotis Tsirigotis, Amalia Vassou, Elina Vervessou, Eirini Katodritou, Maria Gavriatopoulou, Dimitra Gika, Evangelos Terpos, Konstantinos Zervas

Blood (2012) 120 (21): 438.

https://doi.org/10.1182/blood.V120.21.438.438

Published: 2012

Journal Articles

Significant Improvement of the Survival of Patients with Multiple Myeloma Presenting with Severe Renal Impairment After the Introduction of Novel Agents

Meletios A Dimopoulos, MD, Sosana Delimpasi, Eirini Katodritou, Eleftheria Hatzimichael, MD, PhD, Marie-Christine Kyrtsonis, Panagiotis Repousis, Zafiris Kartasis, Agapi Parcharidou, Michalis Michael, Eurydiki Michalis, Dimitra Gika, Argiris Symeonidis, MD, PhD, Konstantinos Zervas, Evangelos Terpos, Efstathios Kastritis

Blood (2012) 120 (21): 948.

https://doi.org/10.1182/blood.V120.21.948.948

Published: 2012

Journal Articles

A phase 1/2 study of lenalidomide with low-dose oral cyclophosphamide and low-dose dexamethasone (RdC) in AL amyloidosis

Efstathios Kastritis, Evangelos Terpos, Maria Roussou, Maria Gavriatopoulou, Constantinos Pamboukas, Ioannis Boletis, Smaragda Marinaki, Theofanis Apostolou, Nikitas Nikitas, Georgios Gkortzolidis, Eurydiki Michalis, Sossana Delimpasi, Meletios A. Dimopoulos

Blood (2012) 119 (23): 5384–5390.

https://doi.org/10.1182/blood-2011-12-396903

Published: 2012

Includes: Supplemental data

Journal Articles

Frequency and Prognostic Significance of Hypercalcemia in Patients with Multiple Myeloma: An Analysis of the Database of the Greek Myeloma Study Group

Efstathios Kastritis, Eirini Katodritou, Anastasia Pouli, Eleftheria Hatzimichael, Sosana Delimpasi, Eurydiki Michalis, Athanasios Zomas, Zafiris Kartasis, Agapi Parcharidou, Dimitra Gika, Panagiotis Repousis, Ekaterini Stefanoudaki, Argiris Symeonidis, Panayiotis Panayiotidis, Konstantinos Konstantopoulos, Evangelos Terpos, Meletios Athanasios Dimopoulos, MD

Blood (2011) 118 (21): 5083.

https://doi.org/10.1182/blood.V118.21.5083.5083

Published: 2011

Journal Articles

Clinical Features and Outcome of Newly Diagnosed, Symptomatic Patients with Multiple Myeloma ≥80 Years of Age: An Analysis of the Greek Myeloma Study Group

Meletios Athanasios Dimopoulos, MD, Efstathios Kastritis, Sosana Delimpasi, Eirini Katodritou, Eleftheria Hatzimichael, Marie-Christine Kyrtsonis, Panagiotis Repousis, Maria Tsirogianni, MD, Zafiris Kartasis, Agapi Parcharidou, Michalis Michael, Eurydiki Michalis, Dimitra Gika, Argiris Symeonidis, Evangelos Terpos, Konstantinos Zervas

Blood (2011) 118 (21): 5084.

https://doi.org/10.1182/blood.V118.21.5084.5084

Published: 2011

Journal Articles

Characteristics and Clinical Course of Myeloma in Patients 40 Years of Age or Younger: A Study of the Greek Myeloma Study Group

Argiris Symeonidis, Efstathios Kastritis, Anastasia Sioni, Sosana Delimpasi, Eirini Katodritou, Eurydiki Michalis, Panagiotis Repousis, Zafiris Kartasis, Nora-Athina Viniou, Konstantinos Zervas, Evangelos Terpos, Meletios Athanasios Dimopoulos, MD

Blood (2011) 118 (21): 5085.

https://doi.org/10.1182/blood.V118.21.5085.5085

Published: 2011

Journal Articles

Comparison of the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI), Modification of Diet in Renal Disease (MDRD) Study Equations and A Formula Based on Cystatin-C and Serum Creatinine for the Estimation of Glomerular Filtration Rate in Patients with Multiple Myeloma; Is It Time to Change From MDRD to CKD-EPI Equation?

Meletios Athanasios Dimopoulos, MD, Efstathios Kastritis, Eirini Katodritou, Anastasia Pouli, Eurydiki Michalis, Dimitrios Christoulas, Maria Gkotzamanidou, Ioannis Papassotiriou, Konstantinos Zervas, Evangelos Terpos

Blood (2011) 118 (21): 5091.

https://doi.org/10.1182/blood.V118.21.5091.5091

Published: 2011

Journal Articles

Primary Therapy of Waldenström's Macroglobulinemia (WM) with Weekly Bortezomib, Low-Dose Dexamethasone and Rituximab (BDR): A Phase II Study of the European Myeloma Network

Meletios A. Dimopoulos, Ramón García-Sanz, Maria Gavriatopoulou, Pierre Morel, Marie-Christine Kyrtsonis, Eirini Katodritou, Eurydiki Michalis, Zafiris Kartasis, Xavier Leleu, MD, PhD, Giovanni Palladini, Alessandra Tedeschi, Dimitra Gika, Evangelos Terpos, Giampaolo Merlini, Efstathios Kastritis, Pieter Sonneveld

Blood (2010) 116 (21): 1941.

https://doi.org/10.1182/blood.V116.21.1941.1941

Published: 2010

Journal Articles

No Significant Improvement In the Outcome of Patients with Waldenström's Macroglobulinemia Treated Over the Last 25 Years

Blood (2010) 116 (21): 3032.

https://doi.org/10.1182/blood.V116.21.3032.3032

Published: 2010

Journal Articles

The International Scoring System (ISS) for Multiple Myeloma Remains a Robust Prognostic Tool Independently of Patients' Renal Function

Blood (2010) 116 (21): 3036.

https://doi.org/10.1182/blood.V116.21.3036.3036

Published: 2010

Journal Articles

Long Term Follow up of the Combination of Bortezomib with Dexamethasone as Initial Treatment for AL Amyloidosis

Efstathios Kastritis, Maria Roussou, Magdalini Migkou, Maria Gavriatopoulou, Constantinos Pamboukas, Sosana Delimpassi, Evelina Charitaki, Eurydiki Michalis, Kaladaridou Anna, Plastiras Sotirios, Dimitrios Gogos, Agrios Ioannis, Evangelos Terpos, Meletios A. Dimopoulos

Blood (2010) 116 (21): 3048.

https://doi.org/10.1182/blood.V116.21.3048.3048

Published: 2010

Journal Articles

High Serum Lactate Dehydrogenase (LDH) Is An Important Prognostic Factor in the Era of Novel Agents and Adds to the Prognostic Value of the International Staging System (ISS) in Patients with Multiple Myeloma.

Dimopoulos A. Dimopoulos, Maria Roussou, Anastasia Pouli, Eirini Katodritou, Argiris Symeonidis, Eurydiki Michalis, Vassiliki Grigoraki, Nikolaos Anagnostopoulos, Athanasios Zomas, Sosana Delimpasi, Agapi Parharidou, Zafiris Kartasis, Nora-Athina Viniou, Dimitra Gika, Evangelos Terpos, Theofanis Economopoulos, Konstantinos Zervas

Blood (2009) 114 (22): 1819.

https://doi.org/10.1182/blood.V114.22.1819.1819

Published: 2009

NARROW

BDR in newly diagnosed patients with WM: final analysis of a phase 2 study after a minimum follow-up of 6 years

Real-World Data on Clinical Characteristics, Prognosis and Outcome of Primary Plasma Cell Leukemia: A Study of the Greek Myeloma Study Group in the Era of Novel Agents

Hypercalcemia Remains an Adverse Prognostic Factor for Newly Diagnosed Patients with Symptomatic Multiple Myeloma in the Era of Novel Anti-Myeloma Therapies, Independently of Age, ISS Stage and Treatment Type: An Analysis of 2129 Patients

No Survival Improvement for Central Nervous System Multiple Myeloma By the Use of Novel Anti-Myeloma Agents: The Greek Myeloma Study Group Experience

Preserved Levels Of Uninvolved Immunoglobulins Are Associated With Better Overall Survival In Patients With Multiple Myeloma Independently Of Disease Burden: A Role For The Immune System?

Competing Risk Survival Analysis In Patients With Symptomatic Waldenström’s Macroglobulinemia (WM): Disease Unrelated Mortality Accounts For Differences In Survival In Patients >75 Years

Primary therapy of Waldenström macroglobulinemia (WM) with weekly bortezomib, low-dose dexamethasone, and rituximab (BDR): long-term results of a phase 2 study of the European Myeloma Network (EMN)

The Chronic Kidney Disease-Epidemiology Collaboration-Cystatin C (CKD-EPI-CysC) Equation Has an Independent Prognostic Value for Overall Survival in Newly-Diagnosed Patients with Symptomatic Multiple Myeloma: Comparison with 3 Other Equations for GFR Estimation

Primary Treatment of Waldenstrom's Macroglobulinemia with Dexamethasone, Rituximab and Cyclophosphamide (DRC): Final Analysis of a Phase II Study

Significant Improvement of the Survival of Patients with Multiple Myeloma Presenting with Severe Renal Impairment After the Introduction of Novel Agents

A phase 1/2 study of lenalidomide with low-dose oral cyclophosphamide and low-dose dexamethasone (RdC) in AL amyloidosis

Frequency and Prognostic Significance of Hypercalcemia in Patients with Multiple Myeloma: An Analysis of the Database of the Greek Myeloma Study Group

Clinical Features and Outcome of Newly Diagnosed, Symptomatic Patients with Multiple Myeloma ≥80 Years of Age: An Analysis of the Greek Myeloma Study Group

Characteristics and Clinical Course of Myeloma in Patients 40 Years of Age or Younger: A Study of the Greek Myeloma Study Group

Primary Therapy of Waldenström's Macroglobulinemia (WM) with Weekly Bortezomib, Low-Dose Dexamethasone and Rituximab (BDR): A Phase II Study of the European Myeloma Network

No Significant Improvement In the Outcome of Patients with Waldenström's Macroglobulinemia Treated Over the Last 25 Years

The International Scoring System (ISS) for Multiple Myeloma Remains a Robust Prognostic Tool Independently of Patients' Renal Function

Long Term Follow up of the Combination of Bortezomib with Dexamethasone as Initial Treatment for AL Amyloidosis

High Serum Lactate Dehydrogenase (LDH) Is An Important Prognostic Factor in the Era of Novel Agents and Adds to the Prognostic Value of the International Staging System (ISS) in Patients with Multiple Myeloma.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only